Actually the failure of Ebolacide has a lot to do with the current stock price. It disproved the notion that NNVC has a straightforward plug-n-play solution to any viral disease. The nanoviricide method just doesn't work for some viruses. Also, one of the main reason for the Ebolacide push was the expectation that demonstrating efficacy in rodents and then primates would allow NNVC to go straight to clinical trials, without multi-kg tox tests. That was a bust. Had Ebolacide worked we'd still see declining stock prices due to the long wait for 'cide scale up, but the price would probably be in the 3s, not the 1s.
News 
Market Data 
Discover 
AI
